GLP-1 / GIP Dual Agonist — Most Effective Available

Tirzepatide

Mounjaro® · Zepbound®

The newest and most effective FDA-approved weight loss medication. Tirzepatide activates two hunger-regulating hormones at once — delivering results that exceed every other medication in its class.

What Is Tirzepatide?

Tirzepatide is the first in a new class of medications called dual GIP/GLP-1 receptor agonists. While semaglutide activates only the GLP-1 receptor, tirzepatide activates both GLP-1 and GIP — two gut hormones that work together to regulate appetite, insulin, and fat storage.

In the SURMOUNT-1 clinical trial — the most significant weight loss trial in decades — patients using tirzepatide lost an average of 22.5% of their body weight over 72 weeks, outperforming every prior medication and rivaling results seen with bariatric surgery.

SURMOUNT-1 Trial Results

22.5% Average body weight reduction at highest dose

91% Of participants lost at least 5% of body weight

57% Of participants lost at least 20% of body weight

72 weeks Duration of SURMOUNT-1 trial (~1.5 years)

Key Benefits

Up to 22% reduction in body weight — highest of any FDA-approved medication

Activates both GLP-1 and GIP hormone receptors simultaneously

Significantly greater weight loss than semaglutide alone in head-to-head trials

Powerful appetite suppression and reduced food cravings

Improves blood sugar, A1C, blood pressure, and triglycerides

Once-weekly injection with a simple auto-injector pen

FDA-approved for Type 2 diabetes (Mounjaro) and weight loss (Zepbound)

Effective for patients who plateaued or didn't respond to other GLP-1s

Is Tirzepatide Right for You?

Tirzepatide may be a good fit if you:

Have a BMI ≥ 30, or ≥ 27 with a weight-related condition
Want the highest level of efficacy currently available
Have used semaglutide but want to try a more potent option
Have Type 2 diabetes and want dual weight and blood sugar management
Are committed to ongoing provider check-ins

Contraindications

Tirzepatide is not appropriate if you have:

Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
History of severe pancreatitis
Severe kidney or gastrointestinal disease
Are pregnant or planning pregnancy

What to Expect: Dosing Timeline

Weeks 1–4 2.5 mg weekly

Starting dose — allows your body to adjust and minimizes early side effects

Weeks 5–8 5 mg weekly

First titration — noticeable appetite reduction begins

Weeks 9–16 7.5 mg weekly

Significant hunger suppression, energy improvements common

Week 17+ 10–15 mg weekly

Maintenance dose — maximum therapeutic effect at highest tolerated dose

Titration is gradual to minimize nausea and GI side effects. Your provider adjusts based on your response.

Start With a Consultation

We'll evaluate your eligibility, review your health history, and help determine whether tirzepatide is the right choice for your goals.

Book Consultation Compare All Medications